Can F/TAF be used for 211 post-exposure prophylaxis and related usage instructions?

F/TAF (F/TAF) is a compound antiviral drug composed of tenofovir disoproxil fumarate (TAF) and entecavir fumarate (F), mainly used for the treatment of HIV infection. Its mechanism of action is to block the replication of the virus by inhibiting the activity of HIVreverse transcriptase, thereby controlling the spread of the virus in the body. Although F/TAFhas shown good efficacy in HIV treatment, its application in HIV post-exposure prophylaxis (PEP, post-exposure prophylaxis) still requires caution.

According to clinical guidelines, the current preferred regimen for HIV PEP is usually a three-drug combination therapy, including two nucleoside reverse transcriptase inhibitors (such as TAF/FTC) plus an integrase inhibitor (such as dolutegravir). Although Dakovo contains TAF, it lacks a third drug. Therefore, using F/TAF alone for PEP has not been recommended by guidelines and may not provide the best post-exposure prophylaxis.

In terms of usage guidance, if you consider using F/TAF for PEP, you need to start it as early as possible within 72 hours after exposure, and strictly follow the doctor's instructions to complete the complete course of 28 days. During treatment, liver and kidney function and blood indicators should be monitored regularly, and possible adverse reactions should be paid attention to, such as mild nausea, fatigue or changes in renal function. After the course of treatment, an HIV antibody test is also required to ensure that no viral infection has occurred.

In general, Dakovo (F/TAF) cannot be used alone as the standard first choice in HIV post-exposure prophylaxis, and its main value is still in HIV treatment. For people with high risk of exposure, priority should be given to the three-drug PEP regimen recommended by the guideline. At the same time, under the guidance of professional doctors, it is evaluated based on individual circumstances whether F/TAF can be included in the combination regimen to achieve safe and effective post-exposure prophylaxis.

Reference link:https://www.drugs.com